Stocktube video
13/02/2012

Immupharma CEO says its flagship product, Lupuzor, has great potential

View full size
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: IMM
Latest Price: 63.50p  (-0.98% Descending)
52-week High: 100.00p
52-week Low: 57.00p
Market Cap: 51.77M
1 year chart
1 day chart
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
ImmuPharma PLC
www.immupharma.com

ImmuPharma plc is a drug discovery and development company. The Company, along with its subsidiaries, is principally engaged in investing in pharmaceutical research and development companies. The Company has operations in Mulhouse, France and Basle, Switzerland. The ImmuPharma plc focuses to develop drugs to treat serious medical conditions. It has five drugs in development to treat: lupus, cancer, severe pain, highly resistant infections, such as methicillin-resistant staphylococcus aureus (MRSA) and inflammatory and allergic disorders. Its wholly owned subsidiaries include ImmuPharma (UK) Limited, which is a holding company; ImmuPharma (France) SA, which is engaged in pharmaceutical research and development, and ImmuPharma AG, which is engaged in pharmaceutical research and development.

Pdf

ImmuPharma: Two directors increase holdings in firm

24th Jan 2012, 2:31 pm by Giles Gwinnett  ImmuPharma said two non-executive directors had increased their holding in the firm by each buying shares worth around £50,000

ImmuPharma (LON:IMM) said two non-executive directors had increased their holding in the firm by each buying shares worth almost £50,000.

Dr Franco di Muzio bought 60,950 shares at 81 pence per share yesterday (January 23) for around £49,370, said the drug discovery and development group.

Meanwhile, Dr Ajay Agrawal acquired 62,169 shares today (January 24) at 80 pence at a cost of around £49,735.

The London-based company has operations in France and Switzerland and has five drugs in development.

Last November, broker Merchant Securities started coverage on the company with a ‘buy’ recommendation and 323 pence share price target.

That valuation was based mainly on the potential of the company’s Lupuzor treatment for the auto-immune disease lupus, which has been given the regulatory green light to go into phase III clinical trials.

Shares in the company are currently trading at 80 pence each.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.